TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $122.70.

TMDX has been the subject of several recent research reports. Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Piper Sandler dropped their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Finally, Oppenheimer reiterated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the business. Driehaus Capital Management LLC boosted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares during the period. Geode Capital Management LLC grew its holdings in shares of TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after purchasing an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after purchasing an additional 6,634 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Down 1.4 %

Shares of NASDAQ TMDX opened at $57.20 on Friday. The stock has a market capitalization of $1.92 billion, a PE ratio of 60.85 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a fifty day moving average of $71.50 and a 200-day moving average of $118.10. TransMedics Group has a 52-week low of $56.03 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.12) EPS. On average, analysts anticipate that TransMedics Group will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.